Literature DB >> 22134627

A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study.

Rory F McQuillan1, Ernest Chiu, Sharon Nessim, Charmaine E Lok, Janet M Roscoe, Paul Tam, Sarbjit Vanita Jassal.   

Abstract

BACKGROUND AND OBJECTIVES: Infectious complications remain a significant cause of peritoneal dialysis (PD) technique failure. Topical ointments seem to reduce peritonitis; however, concerns over resistance have led to a quest for alternative agents. This study examined the effectiveness of applying topical Polysporin Triple ointment (P(3)) against mupirocin in a multi-centered, double-blind, randomized controlled trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: PD patients routinely applied either P(3) or mupirocin ointment to their exit site. Patients were followed for 18 months or until death or catheter removal. The primary study outcome was a composite endpoint of exit-site infection (ESI), tunnel infection, or peritonitis.
RESULTS: Seventy-five of 201 randomized patients experienced a primary outcome event (51 peritonitis episodes, 24 ESIs). No difference was seen in the time to first event for P(3) (13.2 months; 95% confidence interval, 11.9-14.5) and mupirocin (14.0 months; 95% confidence interval, 12.7-15.4) (P=0.41). Twice as many patients reported redness at the exit site in the P(3) group (14 versus 6, P=0.10). Over the complete study period, a higher rate per year of fungal ESIs was seen in patients using P(3) (0.07 versus 0.01; P=0.02) with a corresponding increase in fungal peritonitis (0.04 versus 0.00, respectively; P<0.05).
CONCLUSIONS: This study shows that P(3) is not superior to mupirocin in the prophylaxis of PD-related infections. Colonization of the exit site with fungal organisms is of concern and warrants further study. As such, the use of P(3) over mupirocin is not advocated in the prophylaxis of PD-related infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134627      PMCID: PMC3280035          DOI: 10.2215/CJN.07970811

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  24 in total

1.  Mupirocin once weekly reduces the incidence of catheter exit-site infection in peritoneal dialysis patients.

Authors:  N A Al-Hilali; V T Ninan; H A Al-Humoud; M R N Nampoory; K V Johny
Journal:  Perit Dial Int       Date:  2005 Jan-Feb       Impact factor: 1.756

2.  The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital.

Authors:  Christopher Thiam-Seong Lim; Kok-Seng Wong; Marjore Wai-Yin Foo
Journal:  Nephrol Dial Transplant       Date:  2005-07-26       Impact factor: 5.992

3.  Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population.

Authors:  Sandeep Mahajan; Suresh C Tiwari; Vikram Kalra; Dipankar M Bhowmik; Sanjay K Agarwal; Suresh C Dash; Parveen Kumar
Journal:  Perit Dial Int       Date:  2005 Sep-Oct       Impact factor: 1.756

4.  The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.

Authors:  E Thodis; P Passadakis; S Panagoutsos; D Bacharaki; A Euthimiadou; V Vargemezis
Journal:  Adv Perit Dial       Date:  2000

5.  Long-term follow-up of the Hemodialysis Infection Prevention with Polysporin Ointment (HIPPO) Study: a quality improvement report.

Authors:  Marisa Battistella; Cynthia Bhola; Charmaine E Lok
Journal:  Am J Kidney Dis       Date:  2011-01-08       Impact factor: 8.860

6.  Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.

Authors:  Judith Bernardini; Filitsa Bender; Tracey Florio; James Sloand; Linda Palmmontalbano; Linda Fried; Beth Piraino
Journal:  J Am Soc Nephrol       Date:  2004-12-29       Impact factor: 10.121

7.  Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: a single centre Indian experience.

Authors:  K N Prasad; N Prasad; A Gupta; R K Sharma; A K Verma; A Ayyagari
Journal:  J Infect       Date:  2004-01       Impact factor: 6.072

8.  Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.

Authors:  E Thodis; S Bhaskaran; P Pasadakis; J M Bargman; S I Vas; D G Oreopoulos
Journal:  Perit Dial Int       Date:  1998 May-Jun       Impact factor: 1.756

9.  Hemodialysis infection prevention with polysporin ointment.

Authors:  Charmaine E Lok; Kenneth E Stanley; Janet E Hux; Robert Richardson; Sheldon W Tobe; John Conly
Journal:  J Am Soc Nephrol       Date:  2003-01       Impact factor: 10.121

10.  Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site.

Authors:  Linda Uttley; Anand Vardhan; Sundeep Mahajan; Ben Smart; Alastair Hutchison; Ram Gokal
Journal:  J Nephrol       Date:  2004 Mar-Apr       Impact factor: 3.902

View more
  18 in total

Review 1.  Peritoneal Dialysis-Associated Peritonitis.

Authors:  Cheuk-Chun Szeto; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-08       Impact factor: 8.237

2.  Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis: Multinational Nominal Group Technique Study.

Authors:  Karine E Manera; David W Johnson; Jonathan C Craig; Jenny I Shen; Lorena Ruiz; Angela Yee-Moon Wang; Terence Yip; Samuel K S Fung; Matthew Tong; Achilles Lee; Yeoungjee Cho; Andrea K Viecelli; Benedicte Sautenet; Armando Teixeira-Pinto; Edwina Anne Brown; Gillian Brunier; Jie Dong; Tony Dunning; Rajnish Mehrotra; Saraladevi Naicker; Roberto Pecoits-Filho; Jeffrey Perl; Martin Wilkie; Allison Tong
Journal:  Clin J Am Soc Nephrol       Date:  2018-12-20       Impact factor: 8.237

Review 3.  Peritoneal dialysis associated infections: An update on diagnosis and management.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2012-08-06

Review 4.  Peritoneal dialysis-related infections recommendations: 2016 update. What is new?

Authors:  Vassilios Liakopoulos; Olga Nikitidou; Theofanis Kalathas; Stefanos Roumeliotis; Marios Salmas; Theodoros Eleftheriadis
Journal:  Int Urol Nephrol       Date:  2017-06-01       Impact factor: 2.370

Review 5.  Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.

Authors:  Bradley A Warady; Sevcan Bakkaloglu; Jason Newland; Michelle Cantwell; Enrico Verrina; Alicia Neu; Vimal Chadha; Hui-Kim Yap; Franz Schaefer
Journal:  Perit Dial Int       Date:  2012-06       Impact factor: 1.756

6.  The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients.

Authors:  Anouk T N van Diepen; George A Tomlinson; Sarbjit V Jassal
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-28       Impact factor: 8.237

7.  Identification of Targets for Prevention of Peritoneal Catheter Tunnel and Exit-Site Infections in Low Incidence Settings.

Authors:  Clara Santos; Miguel Pérez-Fontán; Ana Rodríguez-Carmona; María Calvo-Rodríguez; Andrés López-Muñiz; Beatriz López-Calviño; Teresa García-Falcón
Journal:  Perit Dial Int       Date:  2014-10-07       Impact factor: 1.756

Review 8.  A contemporary approach to the prevention of peritoneal dialysis-related peritonitis in children: the role of improvement science.

Authors:  Allison Redpath Mahon; Alicia M Neu
Journal:  Pediatr Nephrol       Date:  2016-10-18       Impact factor: 3.714

Review 9.  Reducing peritoneal dialysis-related peritonitis rate.

Authors:  Anupkumar Shetty
Journal:  Ochsner J       Date:  2014

10.  Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone - Results of a Randomized Open-Label Controlled Trial.

Authors:  Ping-Nam Wong; Gensy M W Tong; Yuk-Yi Wong; Kin-Yee Lo; Shuk-Fan Chan; Man-Wai Lo; Kwok-Chi Lo; Lo-Yi Ho; Cindy W S Tse; Siu-Ka Mak; Andrew K M Wong
Journal:  Perit Dial Int       Date:  2016-04-04       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.